白血病抑制因子（LIF）属IL-6家族，是一种多效性细胞因子，因最早被发现能够抑制小鼠髓系M1白血病细胞增殖并诱导其终末分化而得名。LIF 广泛参与器官、神经发育与再生和免疫调节等反应，对于肿瘤的发展同样具有重要的作用。与抑制白血病细胞生长的作用相反，LIF 通常促进多种类型实体瘤的发展，高表达的LIF 能够促进肿瘤的发生发展、转移、耐药和肿瘤免疫逃逸等，与患者的不良预后相关。聚焦LIF 生理和病理的功能作用及其所调控信号通路的整体性，寻找新的靶向药物，对于LIF通路靶向治疗策略的开发具有重要意义。

Leukemia inhibitory factor （LIF） is a pleiotropic cytokine of the interleukin-6 （IL-6） family, which was first identified as being able to inhibit the proliferation of mouse myeloid M1 leukemia cells and induce their terminal differentiation. LIF is widely involved in the regeneration of organs, neural development, and immune regulation, and also plays an important role in the development of tumors. In contrast to its inhibitory effect on the proliferation of leukemia cells, LIF typically facilitates the progression of many solid tumors. Elevated expression of LIF has been observed to contribute to the development, metastasis, treatment resistance, and evasion of immune response in tumors, hence correlating with a poor prognosis in patients. Focusing on the functions of LIF physiology and pathology and the holistic nature of the signaling pathways it regulates and searching for new targeted drugs is important for the development of targeted therapeutic strategies for the LIF pathway.

国家自然科学基金项目（No. 82274154）；现代中医药海河实验室科技项目（No.22HHZYSS00008）